Could this Large Cap Stock really climb 35.39% in 2024?

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Gold is SOARING - here's what you need to do]( Everything is lining up perfectly for a historic gold bull run. One gold expert says he's found the best way to get in, for just $5. [Click here for full details.]( --------------------------------------------------------------- February 26, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Digital Dollar: Convenience or Control?]( the truth behind the digital dollar. Is it a step towards financial innovation or a leap into surveillance and control? See how you can protect yourself and your money with our free guide. [Protect Your Money ASAP]( --------------------------------------------------------------- [American Tower Corporation]( Symbol: [AMT]( Recent Price: $189.93 Average Analyst Price Target: $237.40 (24.99%) Market Cap: $88.54B Last Year's EPS: $1.02 Consensus EPS Forecast: $1.13 Expected Earnings Date: Feb 27, 2024 Recent Analyst Action: Brendan Lynch, analyst at Barclays, reiterates coverage on [American Tower Corporation (AMT)]( in the Real Estate sector with a Buy rating and a price target of $224 (1 month ago). [TipRanks.com]( also reports that [American Tower Corporation]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $237.40 . The target pricing ranges from a high forecast of $245 down to a low forecast of $224. [American Tower Corporation (AMT)](’s last closing price was $189.93 which would put the average price target at 24.99% upside. Here are 3rd party ratings for [AMT](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Buy, Top 40% (100 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- [Cardlytics, Inc.]( Symbol: [CDLX]( Recent Price: $6.95 Average Analyst Price Target: $9.38 (34.89%) Market Cap: $272.82M Last Year's EPS: $-0.24 Consensus EPS Forecast: $0.00333 Expected Earnings Date: Feb 27, 2024 Recent Analyst Action: Jason Kreyer, analyst at Craig-Hallum, reiterates coverage on [Cardlytics, Inc. (CDLX)]( in the Communication Services sector with a Hold rating and a price target of n/a (3 days ago). [TipRanks.com]( also reports that [Cardlytics, Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $9.38 . The target pricing ranges from a high forecast of $9 down to a low forecast of $12. [Cardlytics, Inc. (CDLX)](’s last closing price was $6.95 which would put the average price target at 34.89% upside. Here are 3rd party ratings for [CDLX](: - TipRanks.com: Hold - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: n/a, n/a [Click for chart >>]( -------------------------------------------------------------------------- [Esperion Therapeutics, Inc.]( Symbol: [ESPR]( Recent Price: $2.61 Average Analyst Price Target: $10.30 (294.64%) Market Cap: $444.79M Last Year's EPS: $-0.46 Consensus EPS Forecast: $-0.42 Expected Earnings Date: Feb 27, 2024 Recent Analyst Action: Jason Zemansky, analyst at Bank of America Securities, reiterates coverage on [Esperion Therapeutics, Inc. (ESPR)]( in the Healthcare sector with a Hold rating and a price target of $2.5 (1 month ago). [TipRanks.com]( also reports that [Esperion Therapeutics, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $10.30 . The target pricing ranges from a high forecast of $9 down to a low forecast of $10. [Esperion Therapeutics, Inc. (ESPR)](’s last closing price was $2.61 which would put the average price target at 294.64% upside. Here are 3rd party ratings for [ESPR](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 39% (99 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [$6,000,000,000,000?]( [~$6 TRILLION: Ex-Wall Street Insider Says: “America’s First Cash Bubble Could Start to Pop.”]( --------------------------------------------------------------- [Avidity Biosciences, Inc.]( Symbol: [RNA]( Recent Price: $14.04 Average Analyst Price Target: $36.00 (156.41%) Market Cap: $1.04B Last Year's EPS: $-0.66 Consensus EPS Forecast: $-0.76 Expected Earnings Date: Feb 27, 2024 Recent Analyst Action: Yanan Zhu, analyst at Wells Fargo, reiterates coverage on [Avidity Biosciences, Inc. (RNA)]( in the Healthcare sector with a Buy rating and a price target of $50 (1 month ago). [TipRanks.com]( also reports that [Avidity Biosciences, Inc.]( currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $36.00 . The target pricing ranges from a high forecast of $50 down to a low forecast of $23. [Avidity Biosciences, Inc. (RNA)](’s last closing price was $14.04 which would put the average price target at 156.41% upside. Here are 3rd party ratings for [RNA](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 32% (80 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message ["I had to race out to Phoenix to see this for myself..."]( Wade – a man who shot to fame by selling a website for $1 million – recently raced to Phoenix, Arizona, where he tested out an AI technology that's sending Wall Street into a feeding frenzy. He told us, "This will be bigger than the internet – and it's not even close!" [Click here to see the exclusive footage of his discovery.]( --------------------------------------------------------------- [Gamida Cell Ltd.]( Symbol: [GMDA]( Recent Price: $0.34 Average Analyst Price Target: $5.00 (1,370.59%) Market Cap: $44.85M Last Year's EPS: $-0.31 Consensus EPS Forecast: $-0.15 Expected Earnings Date: Feb 27, 2024 Recent Analyst Action: Jason Butler, analyst at JMP Securities, reiterates coverage on [Gamida Cell Ltd. (GMDA)]( in the Healthcare sector with a Hold rating (3 weeks ago). [TipRanks.com]( also reports that [Gamida Cell Ltd.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $5.00 . The target pricing ranges from a high forecast of $7 down to a low forecast of $2. [Gamida Cell Ltd. (GMDA)](’s last closing price was $0.34 which would put the average price target at 1,370.59% upside. Here are 3rd party ratings for [GMDA](: - TipRanks.com: Buy - TradingView.com: Strong Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 32% (80 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Is the AI Boom Over?]( All our research tells us AI is about to enter a new phase, with a different set of companies leading the way. And many of these companies are still flying under the radar. Our Weiss Ratings AI specialist, Jon Markman, has homed in on one high-rated AI stock in particular. It’s our pick for The #1 AI Stock of 2023 and Beyond. We reveal more details about this company — and the AI market in general — during our Artificial Intelligence Town Hall. And right now, you can see it for free. [All you need to do is click here.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, DividendPress.com MarketInsidersPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketInsidersPress.com MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software